unmet
medical
need
AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, including conditions which qualify for Orphan drug status.
The Company’s lead programme, AGI-350, is being developed to treat a significant unmet medical need in the critical care setting where effective and efficient delivery of the drug directly to the lung is required to treat a life-threatening, lung-related, condition.
AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
Rule 26 Disclosures
Visitors to this website may access those disclosures required by Rule 26 of the AIM and IEX Rules under “Corporate Governance” in the “Investors” section of this website, or by clicking here